• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

179.25 -2.82 (-1.55%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 982,702
Open 182.55
Bid (Size) 178.96 (100)
Ask (Size) 179.31 (600)
Prev. Close 182.07
Today's Range 175.46 - 182.55
52wk Range 117.30 - 260.19
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗
October 01, 2026
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward... 
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
September 21, 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 31.1% below 52-week high
179.25
117.3052W Low 260.1952W High
1 Week 11.0% below 1-week high
181.751W Low 201.421W High

Axsome Therapeutics, Inc. - Common Stock (AXSM) traded between $117.30 and $260.19 over the past 52 weeks and last traded at $179.25, 31.1% below its 52-week high. Over the past week it ranged between $181.75 and $201.42.

Past 12 Months
-8.1%
-11.6%
-26.6%
+6.4%
+0.3%
+51.2%
1W -$15.84
1M -$23.58
3M -$65.06
6M +$10.75
YTD +$0.56
1Y +$60.68

AXSM was +51.2% over the past year, +6.4% over six months, +0.3% year to date, -8.1% in the last week.

12 Months vs Market
AXSM
+51.2%
DIA
+10.1%
SPY
+15.1%
QQQ
+24.3%
IWM
+16.1%

Over the past 12 months AXSM returned +51.2% versus DIA (Dow) +10.1%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +16.1%.

Volume & Liquidity 1.41× 3-mo avg
Today 982,702 3-mo avg 696.3K
1W
963.5K
1M
695.3K
3M
696.3K
6M
796.0K
YTD
748.9K
1Y
699.1K

AXSM most recently traded 982,702 shares against a 3-month average daily volume of 696.3K.

More News

Read More
News headline image
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction ↗
September 19, 2026
Via MarketBeat
News headline image
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference ↗
September 19, 2026
Via MarketBeat
News headline image
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? ↗
September 18, 2026
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 18, 2026
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 18, 2026
Via The Motley Fool
News headline image
Is Axsome Therapeutics a Buy on the Dip? ↗
September 18, 2026
Via The Motley Fool
News headline image
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
September 17, 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 11, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 10, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
September 02, 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
August 31, 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
August 29, 2026
Via The Motley Fool
News headline image
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run ↗
August 23, 2026
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years ↗
August 17, 2026
Via Benzinga
News headline image
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today ↗
August 13, 2026
Via Benzinga
News headline image
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results ↗
August 11, 2026
Via Benzinga
News headline image
Axsome Therapeutics Q2 Earnings Call Highlights ↗
August 10, 2026
Via MarketBeat
Topics Earnings
News headline image
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 10, 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗
August 04, 2026
Via The Motley Fool
News headline image
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
July 15, 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
July 14, 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
July 10, 2026
Via The Motley Fool
News headline image
Better Growth Buy: Axsome vs Revolution Medicines ↗
July 09, 2026
Via The Motley Fool
Topics Artificial Intelligence

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 179.25
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 8.46B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap